The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells

International Journal of Cancer

Volumn 130, Issue 5, 2012, Pages 1195-1207

  Ruiz Magaña, María J ^a   Rodríguez Vargas, Jose M ^b   Morales, Jorge C ^a   Saldivia, Manuel A ^a   Schulze Osthoff, Klaus ^c   Ruiz Ruiz, Carmen ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

apoptosis; decitabine; leukemia; zebularine

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE; CASPASE 9; DNA METHYLTRANSFERASE; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ZEBULARINE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE ARREST; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA; T LYMPHOCYTE;

APOPTOSIS; AZACITIDINE; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; CYTIDINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA DAMAGE; GENES, P53; HUMANS; LEUKEMIA, T-CELL; MITOCHONDRIA; MUTATION; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES;

EID: 84155172882     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26107     Document Type: Article

References (51)

1. Esteller M,. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005; 45: 629-56. (Pubitemid 40261820)
2. Herman JG, Baylin SB,. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54. (Pubitemid 37448928)
3. Baylin SB,. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; 2 (Suppl 1): S4-S11. (Pubitemid 43135229)
4. Christman JK,. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21: 5483-95. (Pubitemid 34983483)
5. Stresemann C, Lyko F,. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008; 123: 8-13. (Pubitemid 351705186)
6. Kuendgen A, Lubbert M,. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol 2008; 87: 601-11.
7. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU,. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003; 95: 399-409. (Pubitemid 36395260)
8. van Bemmel DM, Brank AS, Eritja R, Marquez VE, Christman JK,. DNA (Cytosine-C5) methyltransferase inhibition by oligodeoxyribonucleotides containing 2-(1H)-pyrimidinone (zebularine aglycon) at the enzymatic target site. Biochem Pharmacol 2009; 78: 633-41.
9. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, Marquez VE, Greer S, Orntoft TF, Thykjaer T, Jones PA,. Preferential response of cancer cells to zebularine. Cancer Cell 2004; 6: 151-8. (Pubitemid 39485687)
10. Boultwood J, Wainscoat JS,. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007; 138: 3-11. (Pubitemid 46889779)
11. Fu WN, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, Newland AC, Jia L,. Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene 2003; 22: 451-5. (Pubitemid 36194341)
12. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM,. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001; 20: 5865-77. (Pubitemid 32937956)
13. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJM, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, et al. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 2007; 212: 330-44. (Pubitemid 47025622)
14. Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 2007; 6: 1718-27. (Pubitemid 46954048)
15. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD,. DNA methylation inhibitor 5-aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 2008; 28: 752-71.
16. Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, Herman JG, Gore SD,. p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 2008; 27: 3615-23. (Pubitemid 351793797)
17. Schmelz K, Wagner M, Dorken B, Tamm I,. 5-Aza-2′-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 2005; 114: 683-95. (Pubitemid 40344429)
18. Tamm I, Wagner M, Schmelz K,. Decitabine activates specific caspases downstream of p73 in myeloid leukemia. Ann Hematol 2005; 84 (Suppl 1): 47-53.
19. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, Wei Y, Jelinek J, Issa JP, Garcia-Manero G,. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 2008; 22: 1529-38.
20. Taylor KH, Pena-Hernandez KE, Davis JW, Arthur GL, Duff DJ, Shi H, Rahmatpanah FB, Sjahputera O, Caldwell CW,. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res 2007; 67: 2617-25. (Pubitemid 46548948)
21. Yasunaga J, Taniguchi Y, Nosaka K, Yoshida M, Satou Y, Sakai T, Mitsuya H, Matsuoka M,. Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Res 2004; 64: 6002-9. (Pubitemid 39129397)
22. Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, Forestier E, Heyman M, Jonmundsson G, Kanerva J, Schmiegelow K, Soderhall S, Gustafsson MG, et al. DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood 2010; 115: 1214-25.
23. Morales JC, Ruiz-Magaña MJ, Ruiz-Ruiz C,. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition. Mol Immunol 2007; 44: 2587-97. (Pubitemid 46240328)
24. Samraj AK, Sohn D, Schulze-Osthoff K, Schmitz I,. Loss of caspase-9 reveals its essential role for caspase-2 activation and mitochondrial membrane depolarization. Mol Biol Cell 2007; 18: 84-93. (Pubitemid 46066713)
25. Gong J, Traganos F, Darzynkiewicz Z,. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 1994; 218: 314-19. (Pubitemid 24141629)
26. Ruiz-Ruiz MC, Lopez-Rivas A,. p53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells. Cell Death Differ 1999; 6: 271-80. (Pubitemid 29145831)
27. Kubo T, Yamamoto J, Shikauchi Y, Niwa Y, Matsubara K, Yoshikawa H,. Apoptotic speck protein-like, a highly homologous protein to apoptotic speck protein in the pyrin domain, is silenced by DNA methylation and induces apoptosis in human hepatocellular carcinoma. Cancer Res 2004; 64: 5172-7. (Pubitemid 39006535)
28. Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, DeCoteau JF,. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp Hematol 2007; 35: 263-73. (Pubitemid 46135814)
29. Stumpel DJ, Schneider P, van Roon EH, Boer JM, de Lorenzo P, Valsecchi MG, de Menezes RX, Pieters R, Stam RW,. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options. Blood 2009; 114: 5490-8.
30. Khan R, Schmidt-Mende J, Karimi M, Gogvadze V, Hassan M, Ekstrom TJ, Zhivotovsky B, Hellstrom-Lindberg E,. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 2008; 36: 149-57.
31. Cheng J, Haas M,. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990; 10: 5502-9.
32. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP,. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990; 87: 7555-9. (Pubitemid 20341755)
33. Qin T, Jelinek J, Si J, Shu J, Issa JP,. Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 2009; 113: 659-67.
34. Billam M, Sobolewski MD, Davidson NE,. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat 2010; 120: 581-92.
35. Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, Khanna KK,. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene 2010; 29: 6085-9.
36. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H,. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 2008; 112: 2341-51.
37. Yan P, Qu Z, Ishikawa C, Mori N, Xiao G,. Human T-cell leukemia virus type I-mediated repression of PDZ-LIM domain-containing protein 2 involves DNA methylation but independent of the viral oncoprotein tax. Neoplasia 2009; 11: 1036-41.
38. Deng T, Zhang Y,. Possible involvement of activation of P53/P21 and demethylation of RUNX 3 in the cytotoxicity against Lovo cells induced by 5-Aza-2′-deoxycytidine. Life Sci 2009; 84: 311-20.
39. Hoglund A, Nilsson LM, Forshell LP, Maclean KH, Nilsson JA,. Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 2009; 113: 4281-8.
40. Franklin EE, Robertson JD,. Requirement of Apaf-1 for mitochondrial events and the cleavage or activation of all procaspases during genotoxic stress-induced apoptosis. Biochem J 2007; 405: 115-22. (Pubitemid 46999931)
41. Ricci JE, Munoz-Pinedo C, Fitzgerald P, Bailly-Maitre B, Perkins GA, Yadava N, Scheffler IE, Ellisman MH, Green DR,. Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell 2004; 117: 773-86. (Pubitemid 38748893)
42. Schmelz K, Sattler N, Wagner M, Lubbert M, Dorken B, Tamm I,. Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia 2005; 19: 103-11. (Pubitemid 40090084)
43. Zhu WG, Hileman T, Ke Y, Wang P, Lu S, Duan W, Dai Z, Tong T, Villalona-Calero MA, Plass C, Otterson GA,. 5-aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem 2004; 279: 15161-6. (Pubitemid 38618911)
44. Pulukuri SM, Rao JS,. Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2′-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int J Oncol 2005; 26: 863-71.
45. Nieto M, Samper E, Fraga MF, Gonzalez de Buitrago G, Esteller M, Serrano M,. The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine. Oncogene 2004; 23: 735-43. (Pubitemid 38241274)
46. Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ,. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res 2005; 11: 4571-9. (Pubitemid 40825648)
47. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, Lubbert M,. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009; 23: 1019-28.
48. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F,. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006; 66: 2794-800.
49. Lemaire M, Momparler LF, Raynal NJ, Bernstein ML, Momparler RL,. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 2009; 63: 411-16.
50. Marquez VE, Kelley JA, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB, Jones PA,. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci 2005; 1058: 246-54.
51. Shimamoto Y, Koizumi K, Okabe H, Kazuno H, Murakami Y, Nakagawa F, Matsuda A, Sasaki T, Fukushima M,. Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2. Jpn J Cancer Res 2002; 93: 825-33.